Disposable paper-based microfluidics for fertility testing

Sarabi, Misagh Rezapour; Yigci, Defne; Alseed, M. Munzer; Mathyk, Begüm Aydoğan; Ata, Barış; Halicigil, Cihan

doi:10.1016/j.isci.2022.104986

Cited by 17 publications

(11 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microfluidic systems have allowed for leveraging the unique properties of fluid flow at micro- or nanoscale and to develop micrototal analysis systems (μTAS) and lab-on-a-chip (LOC) devices . LOC and μTAS have been essential to the generation of paper-based microfluidics tests, 3D tumor models, and POC pathogen diagnostics . Furthermore, microfluidic systems offer miniaturized reactions, lowering the cost of reagents and the required sample volumes.…”

Section: Current Challenges and Future Prospectsmentioning

confidence: 99%

Loop-Mediated Isothermal Amplification-Integrated CRISPR Methods for Infectious Disease Diagnosis at Point of Care

Yigci,

Atçeken,

Yetisen

et al. 2023

ACS Omega

Self Cite

View full text Add to dashboard Cite

Section: Current Challenges and Future Prospectsmentioning

confidence: 99%

Loop-Mediated Isothermal Amplification-Integrated CRISPR Methods for Infectious Disease Diagnosis at Point of Care

Yigci,

Atçeken,

Yetisen

et al. 2023

ACS Omega

Self Cite

View full text Add to dashboard Cite

“…Microfluidic systems have emerged as powerful tools to operate small sample volumes, couple reactions on a single chip, or mimic biological phenomena. As such microfluidic technologies have given rise to micro-total analysis systems (μTAS) and lab-on-a-chip (LOC) models, which have been utilized for various applications ranging from paper-based microfluidics testing [ 60 ] to 3D tumor modeling [ 61 ] or POC pathogen diagnostics [ 62 ]. Specifically, the development of POC pathogen detection platforms has allowed for the miniaturization of amplification reactions, reducing the required sample volumes as well as the reaction reagents [ 63 ].…”

Section: Point-of-care Platformsmentioning

confidence: 99%

CRISPR-Cas-Integrated LAMP

2022

Self Cite

View full text Add to dashboard Cite

Pathogen-specific point-of-care (PoC) diagnostic tests have become an important need in the fight against infectious diseases and epidemics in recent years. PoC diagnostic tests are designed with the following parameters in mind: rapidity, accuracy, sensitivity, specificity, and ease of use. Molecular techniques are the gold standard for pathogen detection due to their accuracy and specificity. There are various limitations in adapting molecular diagnostic methods to PoC diagnostic tests. Efforts to overcome limitations are focused on the development of integrated molecular diagnostics by utilizing the latest technologies available to create the most successful PoC diagnostic platforms. With this point of view, a new generation technology was developed by combining loop-mediated isothermal amplification (LAMP) technology with clustered regularly interspaced short palindromic repeat (CRISPR)-associated (CRISPR-Cas) technology. This integrated approach benefits from the properties of LAMP technology, namely its high efficiency, short turnaround time, and the lack of need for a complex device. It also makes use of the programmable function of CRISPR-Cas technology and the collateral cleavage activity of certain Cas proteins that allow for convenient reporter detection. Thus, this combined technology enables the development of PoC diagnostic tests with high sensitivity, specificity, and ease of use without the need for complicated devices. In this review, we discuss the advantages and limitations of the CRISPR/Cas combined LAMP technology. We review current limitations to convert CRISPR combined LAMP into pathogen-specific PoC platforms. Furthermore, we point out the need to design more useful PoC platforms using microfabrication technologies by developing strategies that overcome the limitations of this new technology, reduce its complexity, and reduce the risk of contamination.

show abstract

“…[ 9 ] The knowledge consolidation combined with the technology's stated potential has allowed it to extend its applicability to several fields. [ 10 ] As a result, microfluidics is currently implemented in the analysis of residual antibiotics in food, [ 11 ] production of monodisperse emulsions in cosmetics, [ 12 ] fertility testing, [ 13 ] monitoring of blood glucose, [ 14 ] and onsite environmental detection, [ 15 ] as representative examples. Among the different application possibilities, healthcare is one of the fields that can take the most advantage of microfluidics in the entire spectrum of research, development, diagnosis, and therapeutics.…”

Section: Introductionmentioning

confidence: 99%

Recent Advances on Cell Culture Platforms for In Vitro Drug Screening and Cell Therapies: From Conventional to Microfluidic Strategies

Cardoso

Castanheira

Lanceros‐Méndez

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

The clinical translations of drugs and nanomedicines depend on coherent pharmaceutical research based on biologically accurate screening approaches. Since establishing the 2D in vitro cell culture method, the scientific community has improved cell-based drug screening assays and models. Those advances result in more informative biochemical assays and the development of 3D multicellular models to describe the biological complexity better and enhance the simulation of the in vivo microenvironment. Despite the overall dominance of conventional 2D and 3D cell macroscopic culture methods, they present physicochemical and operational challenges that impair the scale-up of drug screening by not allowing a high parallelization, multidrug combination, and high-throughput screening. Their combination and complementarity with microfluidic platforms enable the development of microfluidics-based cell culture platforms with unequivocal advantages in drug screening and cell therapies. Thus, this review presents an updated and consolidated view of cell culture miniaturization's physical, chemical, and operational considerations in the pharmaceutical research scenario. It clarifies advances in the field using gradient-based microfluidics, droplet-based microfluidics, printed-based microfluidics, digital-based microfluidics, SlipChip, and paper-based microfluidics. Finally, it presents a comparative analysis of the performance of cell-based methods in life research and development to achieve increased precision in the drug screening process.

show abstract

Disposable paper-based microfluidics for fertility testing

Cited by 17 publications

References 118 publications

Loop-Mediated Isothermal Amplification-Integrated CRISPR Methods for Infectious Disease Diagnosis at Point of Care

Loop-Mediated Isothermal Amplification-Integrated CRISPR Methods for Infectious Disease Diagnosis at Point of Care

CRISPR-Cas-Integrated LAMP

Recent Advances on Cell Culture Platforms for In Vitro Drug Screening and Cell Therapies: From Conventional to Microfluidic Strategies

Contact Info

Product

Resources

About